World’s first anti-aging TAME trial gets green-light

Latest articles

Exclusive: “Mitlets” hold potential for mitochondria transfusion

Mitrix Bio believes recently discovered blood components may support transfusion of large quantities of healthy mitochondria from donor to patient. Earlier this year, we brought...

Optimise your body and mind by tackling cell stress

Want to live longer and heathier? Combating cell stress is an important first step on your longevity journey. It's a fast-paced, busy world, and we're...

Crypto – pulling a (Moon) Rabbit out a hat for longevity

Angel Versetti on why it makes sense to look at more experimental solutions for longevity. Earlier this week we brought you part one of our...

New webinar will explore the opportunity of ovarian longevity

What does delaying menopause mean in terms of investment activity, societal change and the technologies that will reshape the lives of multiple millions of...

Most read

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Editor's picks

Exclusive: “Mitlets” hold potential for mitochondria transfusion

Mitrix Bio believes recently discovered blood components may support transfusion of large quantities of healthy mitochondria from donor to patient. Earlier this year, we brought...

Optimise your body and mind by tackling cell stress

Want to live longer and heathier? Combating cell stress is an important first step on your longevity journey. It's a fast-paced, busy world, and we're...

Crypto – pulling a (Moon) Rabbit out a hat for longevity

Angel Versetti on why it makes sense to look at more experimental solutions for longevity. Earlier this week we brought you part one of our...

Click the globe for translations.

Groundbreaking TAME trial, which directly targets aging as an endpoint, finally begins this November, reveals lead clinician Dr Nir Barzilai.

After closing the final $40m of its required $75m budget with a donation from a private source, the first drug trial directly targeting aging is set to begin at the end of this year, lead researcher Dr Nir Barzilai has revealed in an exclusive interview with Longevity.Technology.

Back in 2015, when his revolutionary anti-aging trial TAME finally received FDA approval, it would have been forgivable to think that Dr Barzilai had, at last, got past the hard part. But TAME went into financial limbo, with many wondering if it would ever be able to escape. “We wasted valuable time negotiating,” said Dr Barzilai, director of the Institute for Aging Research at the Albert Einstein College of Medicine,“but we’re finally on track.” His trial TAME (Targeting Aging with Metformin) had been stalled for four years while he and his colleagues engaged in funding negotiations with the US NIH (National Institute of Health).

“It was down to their conservative approach over there. They really didn’t understand what we were trying to achieve,” he said.

Longevity.Technology: Truly effective anti-aging pills are a long way away from full realisation. While a number of studies have demonstrated benefits conferred to patients both by metformin and rapamycin, not many expect the drugs to be highly effective at enhancing Longevity. The TAME trial’s green light is very good news for those who want to develop better Longevity drugs in the future. If the trial’s unique structure works, its completion in five years’ time could be the spur for many who have, so far, been discouraged from trialling drugs with aging as a direct endpoint.

The TRL score for this Longevity.Technology domain is currently set at: ‘Technology has completed initial trials and demonstrates preliminary safety data.’

The TRL score for the technology addressed in this article is: “Principles are demonstrated through experimentation.”

For those accustomed to judging the success of a drug trial’s funding acquisition by the safety and efficacy record of its drug, TAME’s funding difficulties could look confusing. Safely used and widely prescribed, the trial’s antidiabetic drug, metformin, has been US FDA approved since 1994. Its use in medical practice extends back into the Middle Ages, where it was extracted from the French lilac and later in France from the 1950s onwards, when the isolated compound was first successfully administered to diabetic patients.

But it is much more the trial structure, rather than the drug itself, that is on trial. Instead of following a traditional structure given to FDA approved trials (that look for a single disease-endpoint) TAME has a composite primary endpoint – of stroke, heart failure, dementia, myocardial infarction, cancer and death. Rather than attempting to cure one endpoint, it will look to delay the onset of any endpoint, extending the years in which subjects remain in good health – their healthspan.

Barzilai believes metformin is the perfect fit for a trial of this kind. In recent years it has been shown to extend the lives of nematodes (or roundworms) by 57% and mice by 6%. In humans, claims abound that metformin-takers are living longer, having fewer cardiovascular episodes and seeing reduced odds of getting cancer.

In a retrospective 2014 analysis [1] conducted by the University of Cardiff of 78,000 adult type 2 diabetics in their 60s, those who took metformin lived longer, on average, than healthy controls of the same age. This has led a growing body of doctors beginning to prescribe the drug off-label, so that their patients may benefit from its purported anti-aging effects.

Such widespread speculation demands deeper scientific investigation. It is TAME’s composite primary endpoint, created with the cooperation of the FDA, that excites Barzilai and his colleagues. They hope that Big Pharma will use it to develop drugs with even more powerful anti-aging effects. The NIH, however, was loath to sponsor a trial with such an unconventional format, and the off-patent status of metformin meant that, while its success would be an excellent win for the public and the Longevity field, few private investors took much interest in donating funds.

This was until the $40m donation, which made up more than half of the required funds for the trial. Steven Austad, scientific director of AFAR (American Federation for Aging Research) the organisation that provided the other $35m, says, “I’m incredibly pleased that TAME is going ahead. We want a pathway that we can use to target aging. Even if metformin doesn’t work, we’ve illuminated a route by which an anti-aging drug can get FDA approval in a relatively short-time frame study of four or five years. This will very likely interest Big Pharma.”

Whether metformin itself is a success or a failure, the trial will very likely revolutionise the way that aging research is done.

As for who provided the $40m funding, Barzilai remains coy, “I can’t tell you who gave us it, but it will be a great story one day!”

Dr. Barzilai’s exclusive interview with Longevity.Technology can be found here.

[1] https://www.ncbi.nlm.nih.gov/pubmed/25041462
Ben Turner
Staff Writer Ben Turner is a writer and journalist based in London. He graduated in 2015 with a Master’s degree in Physics. He is particularly interested in the translation of early scientific discoveries into cutting-edge tech.

Most popular

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

Related articles

Buck Institute awarded $12.7m to join senescence network

NIH award to join SenNet, the Cellular Senescence Network, will enable Buck scientists to identify and characterise senescent cells – recognised as a driver...

Deep learning platform seeks near-term indications of age-related diseases

Arrive co-founder talks combining aging cell biology, drug screening and deep learning technology in the quest to discover novel antiaging targets. Silicon Valley and Singapore-based...

A new approach to reversing tissue aging

Exploring Revel’s enzyme-based approach to breaking down crosslinks and targeting tissue aging. Last year, a startup called Revel Pharmaceuticals emerged from the labs at Yale...

Ovarian aging – your questions answered

Ovarian longevity and the significance of ovarian aging is poorly understood – our video aims to change that. Join our Scientific Editor Daragh Campbell as...

Learning lessons from clinical trial failure

Metabesity 2021: Joan Mannick talks longevity scientific breakthroughs, healthspan endpoints, her new role at Life Biosciences, and what can be learned from resTORbio’s clinical...